Status:
UNKNOWN
Is it Effective to Treat Patients With Blastocystis Hominis Infection?
Lead Sponsor:
University of Lausanne Hospitals
Conditions:
Blastocystis Hominis Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The objective of this study is to determine whether in the setting of primary health care it is effective to treat with metronidazole returning travellers with gastrointestinal symptoms and B. hominis...
Detailed Description
Prevalence of B. hominis is between 30-50% in developing countries. Many travellers visit developing countries and are therefore at risk to be infected by this parasite. It's frequent that travellers ...
Eligibility Criteria
Inclusion
- ≥ 18 years
- Gastrointestinal symptoms for more than 10 days
- B. hominis in any quantity in at least one stool specimen out of 3 examined
- No other pathogenic micro-organism identified
Exclusion
- Fever \> 37.5°
- bloody diarrhoea
- weight loss \> 10% of usual body weight
- significant decrease of general condition
- oncological diseases
- immune deficiencies
- known chronic intestinal diseases
- use of anti-protozoan drugs in the last 2 weeks
- use of anti-coagulant treatment or antabuse
- pregnant and lactating women
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01521403
Start Date
November 1 2012
End Date
December 30 2022
Last Update
August 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Travel Clinic, Department of Ambulatory Care and Community Medicine, University Hospital of Lausanne, Switzerland
Lausanne, Canton of Vaud, Switzerland, 1011